J.P. Morgan

Novo Nordisk, J.P. Morgan, Eli Lilly, Wegovy, GLP-1, obesity, cardiovascular,

Novo Nordiskā€™s Wegovy boosts heart health, J.P. Morgan predicts $71B GLP-1 market by 2032

Anika Sharma

The demand for Novo Nordisk’s obesity medications is surging, with production capacity being the primary limiting factor in the short ...